Dane Ediger

Dr. Dane Ediger

orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in The Lancet Respiratory Medicine
Verified
Journal Article
Closed access
WBWilliam W Busse
William W Busse
EBEugene R Bleecker
Eugene R Bleecker
JFJ Mark FitzGerald
J Mark FitzGerald
GFGary T Ferguson
Gary T Ferguson
PBPeter Barker
Peter Barker
LLLan Le
Lan Le

1 January 1999 in Journal of Asthma
Verified
Journal Article
Closed access
SBSevim Bavbek
Sevim Bavbek
GÇGülfem Çelik
Gülfem Çelik
Dane EdigerDane Ediger
Dane Ediger
DMDilşad Mungan
Dilşad Mungan
YDYavuz Selim Demirel
Yavuz Selim Demirel
ZMZeynep Misirhgil
Zeynep Misirhgil
Intolerance or idiosyncrasy to acetylsalicylic acid (ASA) and other nonsteroidal anti-inflammatory drugs (NSAIDs) is a crucial problem because these drugs are frequently used in medical treatment. In this study, we tested whether nimesulide, a selective cyclooxygenase-2 (COX-2) inhibitor, might be a valid alternative for patients with histories of adverse reaction to ASA or NSAIDs. A single-blind, placebo-controlled oral challenge procedure was applied to 60 adult patients (19 male, 41 female; with a mean age of 40.31 +/- 10.44 years, range 20-68 years) with a reliable history of ASA/NSAIDs-intolerance. According to history, the clinical presentations of intolerance were urticaria/angioedema in 32 patients, anaphylactoid reaction in 2 patients, respiratory reaction in 19 patients, and respiratory and cutaneous reaction in 7 patients. Atopy was confirmed by means of skin prick test with inhalant allergens. Oral challenge protocol was started with 25 mg of nimesulide and the remaining 75 mg was given 1 hr later. During the challenge procedure, blood pressure, pulse, nasoocular, pulmonary, and cutaneous symptoms were monitored. Of the 60 patients tested, 55 (91.7%) tolerated the drug with no adverse reaction. Only five (8.3%) patients demonstrated a positive response to oral challenge. The clinical presentations of intolerance to nimesulide were urticaria/angioedema in three patients, mild rhinitis in one patient, and mild dyspnea in one patient. The atopy prevalence was higher, with a ratio of 41.7%, in patients with ASA/NSAIDs intolerance than that of the healthy adult population in Turkey (p < 0.05). We believe that nimesulide can be used as an alternative drug for patients with ASA/NSAIDs intolerance.

21 March 2005 in Clinical & Experimental Allergy
Verified
Journal Article
Closed access
PDF file
Dane EdigerDane Ediger
Dane Ediger
BSB. A. Sin
B. A. Sin
AHAylin Okçu Heper
Aylin Okçu Heper
YAY. Anadolu
Y. Anadolu
ZMZ. Mιsιrlιgil
Z. Mιsιrlιgil

1 January 1999 in Journal of Asthma
Verified
Journal Article
Closed access
PDF file
GÇGülfem Çelik
Gülfem Çelik
DMDilşad Mungan
Dilşad Mungan
SBSevim Bavbek
Sevim Bavbek
BSBetül Sin
Betül Sin
Dane EdigerDane Ediger
Dane Ediger
ZMZeynep Misirlgil
Zeynep Misirlgil
To assess the prevalence of allergic diseases and atopy in adults, a two-step population-based epidemiological study was undertaken in Ankara, the capital city of Turkey. In step 1, a screening questionnaire adapted from the European Community Respiratory Health Survey (ECRHS) was applied in a cross-sectional manner. In step 2, a nested case-controlled design study was conducted and subjects were evaluated in the clinical setting for history, physical examination, skin prick tests (SPTs), and serum total IgE and phadiotop measurements. According to the results, self-reported current asthma prevalence in step 1 was lower compared with that in step 2 (3% vs. 7%, p < 0.05). The prevalences of food and drug allergy were 6.2% and 3.9%, respectively, in step 1, but were not demonstrated in any of the subjects in step 2. The overall prevalence of atopy was 25% after step 2 evaluation. In conclusion, allergic disorders are not uncommon in our adult population; however, sole application of a screening questionnaire appeared to be ineffective in revealing the accurate figures of asthma, and food or drug allergy.

1 March 2006 in Tumori Journal
Verified
Journal Article
Closed access
PDF file
MKMelike Koç
Melike Koç
Dane EdigerDane Ediger
Dane Ediger
FBFerah Budak
Ferah Budak
MKMehmet Karadağ
Mehmet Karadağ
HOHaluk Barbaros Oral
Haluk Barbaros Oral
RGRamazan Oktay Gözü
Ramazan Oktay Gözü
Aims and Background: Matrix metalloproteinase (MMP) family member MMP-9 degrades type IV collagen, which is one of the main constituents of the basement membrane. MMP-9 is closely associated with the invasive and metastatic potential of most types of lung cancer. In this study we investigated the levels of MMP-9 in serum and bronchial lavage fluid from lung cancer patients and compared them with the levels in patients with nonmalignant lung disease. We also attempted to clarify the possible relationship between serum and bronchial lavage fluid MMP-9 levels and histopathology, staging and metastasis of lung cancer. Study Design: The study group consisted of 34 patients with lung cancer. The control group comprised 21 patients with nonmalignant lung disease. MMP-9 levels in serum and bronchial lavage fluid were evaluated by ELISA. Results: MMP-9 levels in serum samples from the group with malignant disease were significantly higher than those from the control group (P 0.05). Serum MMP-9 levels were two-fold higher than those in bronchial lavage, but there was no correlation between bronchial lavage and serum levels in both groups (r = 0.18, P >0.05). In the group with malignant disease, MMP-9 levels in serum and bronchial lavage fluid did not show any relationship with histopathological type and tumor stage. There was a statistically significant correlation between serum MMP-9 levels and local tumor stage in smoking nonsmall cell lung cancer (NSCLC) patients (r = 0.33, P <0.05). Karnofsky scores of lung cancer patients were inversely correlated with MMP-9 levels of serum (r = -0.39, P <0.05) but not of bronchial lavage fluid. Conclusion: From our data it can be concluded that MMP-9 levels of serum but not of bronchial lavage fluid can be helpful in differentiating between malignant and benign lung diseases, and are related to the local stage in NSCLC patients and general clinical status of lung cancer patients.

1 July 2012 in Allergologia et Immunopathologia
Verified
Journal Article
Closed access
SBS. Bavbek
S. Bavbek
IYİ. Yılmaz
İ. Yılmaz
GÇG. Çelik
G. Çelik
OAOmur Aydin
Omur Aydin
FEF.ö. Erkekol
F.ö. Erkekol
ZMZ. Mısırlıgil
Z. Mısırlıgil
There are no country-based data focused on aspirin (ASA)-exacerbated respiratory disease (AERD) in Turkey. To assess the prevalence of AERD in adult patients with asthma. A structured questionnaire was administered via face-to-face interview by a specialist in pulmonology/allergy at seven centres across Turkey. A total of 1344 asthma patients (F/M: 1081/263: 80.5%/19.5%, mean age: 45.7 ± 14.2 years) were enrolled. Atopy rate was 47%. Prevalence of allergic rhinitis, chronic rhinosinusitis/rhinitis, and nasal polyposis (NP) were 49%, 69% and 20%, respectively. Of 270 patients with NP, 171 (63.3%) reported previous nasal polypectomy and 40 (25%) had a history of more than three nasal polypectomies. Aspirin hypersensitivity was diagnosed in 180 (13.6%) asthmatic patients, with a reliable history in 145 (80.5%), and oral ASA provocation test in 35 (19.5%) patients. Clinical presentations of ASA hypersensitivity were respiratory in 76% (n=137), respiratory/cutaneous in 15% (n=27), and systemic in 9% (n=16) of the patients. Multivariate analysis indicated that a family history of ASA hypersensitivity (p: 0.001, OR: 3.746, 95% CI: 1.769-7.929), history of chronic rhinosinusitis/rhinitis (p: 0.025, OR: 1.713, 95% CI: 1.069-2.746) and presence of NP (p<0.001, OR: 7.036, 95% CI: 4.831-10.247) were independent predictors for AERD. This cross-sectional survey showed that AERD is highly prevalent among adult asthmatics and its prevalence seems to be affected by family history of ASA hypersensitivity, history of rhinosinusitis and presence of NP.